(CercleFinance.com) – The combination of Jemperli from GSK and chemotherapy has achieved the main objective of a phase III clinical trial in endometrial cancer, the British laboratory announced on Monday.
The study results showed that this anti-PD-1 antibody combined with chemotherapy had a statistically significant and clinically convincing improvement in the overall survival of patients with advanced or recurrent disease.
In the United States, Jemperli is currently indicated as a monotherapy for the treatment of adult patients with recurrent or advanced endometrial cancer with repair-deficient solid tumors (TsdR) or microsatellite instability high (MSI-H) having progressed with previous treatment using a platinum-containing regimen.
On the London Stock Exchange, GSK shares rose 1.3% following this announcement, marking one of the biggest falls in the FTSE 100 index, which rose 0.7% at the same time.
GSK also renewed its licensing agreement with the American 23andMe on Monday, under the terms of which it will continue to use the genetic testing specialist’s database for the development of new therapies.
23andMe is expected to receive an upfront payment of $20 million as part of the extension of this non-exclusive collaboration agreement.
Copyright (c) 2023 CercleFinance.com. All rights reserved.